Egetis Therapeutics is a Swedish rare-disease company focused on Emcitate (tiratricol), a therapy for MCT8 deficiency (Allan-Herndon-Dudley syndrome), a severe genetic disorder of thyroid hormone transport. Emcitate is approved in the EU as a treatment for this condition and is advancing through U.S. regulatory review. The company concentrates on a high-unmet-need orphan indication rather than broad primary-care markets.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 12.7 | — | -62.9 | — |
| Q2 2025 | 14.5 | — | -77.6 | — |
| Q3 2025 | 17.4 | — | -82.4 | — |
| Q4 2025 | 17.9 | — | -119.7 | — |
| Q1 2026 | 13.4 | 5.5% | -94.5 | — |
All markets — KeepWinning global stock screener
Other companies on Stockholm: Idun Industrier AB (publ) (IDUN B), Swedencare AB (publ) (SECARE), Proact IT Group AB (publ) (PACT), Viva Wine Group AB (VIVA), Fenix Outdoor International AG (FOI B), Nivika Fastigheter AB (publ) (NIVI B)